Loading company…
Psy-link develops yeast fermentation technology to produce psilocybin and other compounds for therapeutic research.
Founded in 2020 and based in Vilnius, Lithuania, Psy-link develops biosynthesis technologies using yeast fermentation, including for psilocybin and other compounds. It works with research institutions, pharmaceutical companies and academic organizations on therapeutic research and drug development. In July 2025, the company raised EUR 501,521 in pre-seed funding led by Coinvest Capital, with Firstpick and Baltic Sandbox Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in